Inactive Instrument

Other languages Capricor Therapeutics Inc Nasdaq

Equities

US14070B1017

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug	Apr. 24
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	Apr. 24
Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference	Mar. 06
Capricor Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29
Capricor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29
Sector Update: Health Care Stocks Ease Late Afternoon	Feb. 27
Sector Update: Health Care Stocks Decline Tuesday Afternoon	Feb. 27
Capricor Secures Meeting With FDA on CAP-1002 Manufacturing Plans; Shares Rise	Feb. 27
Capricor Therapeutics Announces Manufacturing Scale-Up of Cap-1002 Production At New San Diego Facility as It Continues Plans Toward Commercialization	Feb. 20
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2	Jan. 24
Capricor Therapeutics Announces Continuation of Phase 3 Hope-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis	Dec. 11
Capricor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Sector Update: Health Care Stocks Lower Late Afternoon	23-09-29
Sector Update: Health Care	23-09-29
Top Midday Decliners	23-09-29
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	23-09-29
Capricor Therapeutics to Offer 4.9 Million Shares; Meets With US FDA to Discuss CAP-1002 Candidate	23-09-29
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy	23-09-29
Capricor Therapeutics, Inc. Appoints Michael Kelliher to Its Board of Directors	23-09-06
Capricor Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Capricor Therapeutics Inc Nasdaq

Equities

US14070B1017

Other languages

Filters